Cardiology

New research suggests cumulative exposure to PFAS could increase risk of incident hypertension by 71% among midlife women.

Using data from a large study of childhood cancer survivors and NHANES, investigators provide insight into the undertreatment and underdiagnosis of cardiovascular risk factors among survivors of childhood cancer compared to the general US population.

An analysis of the National Inpatient Sample at ENDO 2022 provides insight into the risk of myocardial infarction associated with prediabetes compared against normoglycemic patients.

In a study presented at SLEEP 2022, investigators provide an overview of the impact of obstructive sleep apnea and daytime sleepiness with increased risk of atherosclerotic cardiovascular disease.

Our latest case report from Brady Pregerson, MD, features a man in his early 60s presenting with months of gradually worsening dyspnea on exertion that has been worse for several days. Check out the EKG and determine the correct diagnosis!

A panel of expert cardiologists share their concluding thoughts on management of polyvascular disease in clinical practice.

Cardiologists share unmet needs and emerging approaches to management of patients with polyvascular disease.

Manesh Patel, MD, reviews VOYAGER trial data and expert cardiologists share where they use DPI [dual pathway inhibition] in their practices.

The HTRA1 and CFH risk alleles, family history of AMD, the LOC387715 risk allele, and cardiovascular disease were all linked to an increased risk of AMD.

In the latest edition of Don’t Miss a Beat, hosts Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, are joined by special guest Anjali Owens, MD. An assistant professor of medicine and medical director of the Center for Inherited Cardiac Disease at the Perelman School of Medicine, Owens takes our hosts on a deep dive into the current state of management for oHCM and the impact of the US FDA's approval of mavacamten.

Investigators contribute more detailed understanding of the association between sleeping disorder and cardiovascular event risks.

Late-breaking data from SLEEP 2022 show there may be biological plausibility for cardiovascular risks in excessively sleepy individuals.

After new data from the Diabetes Prevention Program Outcomes Study suggested neither metformin nor lifestyle intervention addressed the cardiovascular risk in patients with prediabetes, we asked experts at ADA 2022 if it was time to rethink metformin as first-line therapy in type 2 diabetes.

A 5-year, real-world study comparing the safety and efficacy of empagliflozin against other glucose-lowering agents, EMPRISE suggests empagliflozin was associated with relative risk reductions for heart failure hospitalization greater than 50% compared with DPP-4 inhibitors and greater than 30% compared with GLP-1 receptor agonists.

Prof. Hertzel Gerstein discusses new ELIXA biomarker findings from ADA 2022.

The diabetologist and professor discusses new findings from the ReTUNE trial, which disparage the utility of BMI in defining diabetes risk and remission opportunity.

New post hoc data from the STEP 1 and 4 trials show an approximate 60% risk reduction of type 2 diabetes over 10 years versus placebo.

Uninsured adults with low income in nonexpansion states experienced worse access and cardiovascular risk factor management compared to insured adults.

Our latest case report from Brady Pregerson, MD, features an elderly male with a past medical history of diabetes and stage 5 CKD presenting with 2 days of nausea, vomiting, and generalized weakness. Check out the EKG and determine the correct diagnosis!

Naomi Fisher, MD, offers perspective on the changing landscape of diabetes management and how the addition of new agents to the ADA's Standards of Care might impact care of patients.

Expert cardiologists discuss data from COMPASS trial and the role of rivaroxaban and low-dose aspirin in treatment of patients with CAD and PAD.

Sahil Parikh, MD, shares how lack of access to or awareness of DPI [dual pathway inhibition] causes many practices and health care providers to face a challenge in treating CAD [coronary artery disease].

HDL-C level >80 mg/dL was associated with higher risk of all-cause and cardiovascular death in patients with CAD, compared with those with normal HDL-C levels.

Expert cardiologists share strategies for educating patients on the treatment and management of hypertrophic cardiomyopathy.

Drs Steve R. Ommen, Martin S. Maron, Javed Butler, and James Januzzi provide insight on the evolving treatment landscape for obstructive hypertrophic cardiomyopathy.